Insider Brief
- Wellcome Leap’s Quantum for Bio (Q4Bio) program concluded its final in-person milestone, with six finalist teams presenting hybrid quantum-classical approaches to biomedical problems.
- Delegates from leading quantum organizations and Nobel laureate John Martinis reviewed results across drug discovery and oncology biomarker identification.
- Winners will be announced in April 2026, with up to $7M in challenge prizes for experimental results on real quantum hardware.
Wellcome Leap’s Quantum for Bio (Q4Bio) program, a $40M research initiative with up to $10M in challenge prizes, has reached its final in-person milestone. This week, the six finalist teams gathered in Marina del Rey to present their findings to a select group of invited delegates drawn from the highest ranks of the global quantum computing field.
The Q4Bio program was launched to answer a deceptively simple question: can today’s quantum computers, noisy and limited as they are, do something genuinely useful for human health? After 30 months and three phases of rigorous evaluation, the teams are presenting their answers.
Delegates invited to review the results include Ryan Babbush of Google Quantum AI, Gopal Karemore of IBM Research, Nathan Baker of Microsoft Quantum, Evgeny Epifanovsky of IonQ, Harry Buhrman and Christopher Langer of Quantinuum, Sam Pallister of PsiQuantum, and Alan Ho of QoLab. John Martinis, the 2025 Nobel Laureate in Physics, will join as a featured guest.
“When we started the program, people didn’t know about any use cases where quantum can definitely impact biology,” said Shihan Sajeed, Q4Bio Program Director at Wellcome Leap. “We now know the fields where quantum can matter.”
The six finalist teams have each developed hybrid quantum-classical approaches, combining quantum processors with classical high-performance computing to tackle biomedical problems ranging from drug discovery to oncology biomarker identification. The gathering in Marina del Rey is not a prize ceremony. Winners will be announced next month, with up to $2M available for teams demonstrating experimental results on quantum hardware with more than 50 qubits, and a $5M grand prize for the team that best meets the program’s full proof criteria on real quantum devices.
The meeting also serves a longer-term purpose. By bringing together leading hardware and software experts as delegates, Wellcome Leap is positioning Q4Bio’s findings as a foundation for future collaboration, ensuring that the research generated across the program continues to inform the field after the competition concludes.
The Q4Bio program represents one of the most structured attempts to date to hold quantum computing to a rigorous clinical standard, requiring teams to benchmark against classical high-performance computing and demonstrate results on actual quantum hardware rather than simulations.
Program winners will be announced in April 2026.
For more details, you can visit the following post.
